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Background: Acute liver failure leads to systemic complications with one of the most dangerous being a decline in
neurological function, termed hepatic encephalopathy. Neurological dysfunction is exacerbated by an increase
of toxic metabolites in the brain that lead to neuroinflammation. Following various liver diseases, hepatic and
circulating chemokines, such as chemokine ligand 2 (CCL2), are elevated, though their effects on the brain
following acute liver injury and subsequent hepatic encephalopathy are unknown. CCL2 is known to activate
microglia in other neuropathies, leading to a proinflammatory response. However, the effects of CCL2 on microglia
activation and the pathogenesis of hepatic encephalopathy following acute liver injury remain to be determined.
Methods: Hepatic encephalopathy was induced in mice via injection of azoxymethane (AOM) in the presence or
absence of INCB 3284 dimesylate (INCB), a chemokine receptor 2 inhibitor, or C 021 dihydrochloride (C021), a chemokine
receptor 4 inhibitor. Mice were monitored for neurological decline and time to coma (loss of all reflexes) was recorded.
Tissue was collected at coma and used for real-time PCR, immunoblots, ELISA, or immunostaining analyses to assess the
activation of microglia and consequences on pro-inflammatory cytokine expression.
Results: Following AOM administration, microglia activation was significantly increased in AOM-treated mice compared
to controls. Concentrations of CCL2 in the liver, serum, and cortex were significantly elevated in AOM-treated mice
compared to controls. Systemic administration of INCB or C021 reduced liver damage as assessed by serum liver enzyme
biochemistry. Administration of INCB or C021 significantly improved the neurological outcomes of AOM-treated mice,
reduced microglia activation, reduced phosphorylation of ERK1/2, and alleviated AOM-induced cytokine upregulation.
Conclusions: These findings suggest that CCL2 is elevated systemically following acute liver injury and that CCL2 is
involved in both the microglia activation and neurological decline associated with hepatic encephalopathy. Methods
used to modulate CCL2 levels and/or reduce CCR2/CCR4 activity may be potential therapeutic targets for the
management of hepatic encephalopathy due to acute liver injury.
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Hepatic encephalopathy is a serious neuropsychiatric
complication of both acute liver failure and chronic
liver diseases with the potential to affect health-related
quality of life, clinical management strategies, priority
for liver transplantation, and patient survival [1]. The
etiology and progression of hepatic encephalopathy due to
acute liver failure and chronic liver diseases differs signifi-
cantly. For example, hepatic encephalopathy resulting from
acute liver failure causes altered mental states and cogni-
tive disruptions that can progress to coma in hours or days
[2]. Conversely, during cirrhosis, hepatic encephalopathy
develops slowly, with many patients having altered sleep
patterns and cognitive issues which can progress to more
severe symptomology if no therapeutic intervention is
given [3]. Associated with these differences in neurological
presentation, the disease processes that generate hepatic
encephalopathy due to acute and chronic liver failure differ
significantly. For example, the presence of cerebral edema
with elevated intracranial pressure is only observed in
patients with acute liver failure [4]. However, the one
pathological process common to hepatic encephalopathy
that is independent of the type or longevity of liver insult
is the activation of neuroinflammatory cascades.
A substantial body of evidence exists suggesting a role
for proinflammatory mechanisms in the progression of
hepatic encephalopathy. In patients and in animal models
of hepatic encephalopathy, systemic inflammation causes
worsening of the encephalopathy, and proinflammatory
signals may act synergistically with ammonia toxicity to
bring about the neurological complications of acute and
chronic liver failure [1]. Indeed, tumor necrosis factor-α,
interleukin (IL)-1β, and IL-6 levels were increased in
patients with acute liver failure [5] as well as in rodent
models of acute liver failure [6], and are thought to
contribute to cerebral edema and intracranial pressure.
In addition, the number of activated microglia is in-
creased in rodent models of hepatic encephalopathy
and the use of anti-inflammatory agents, such as mino-
cycline, inhibit the microgliosis and delay the onset of
neurological symptoms [7].
In addition to the proinflammatory cytokines, neuro-
inflammation can be regulated by chemokines or chemotac-
tic cytokines. They are involved in cell-cell communication,
effecting a directional migration and activating various cell
types of the immune system. In the brain, the chemokine lig-
and 2 (CCL2 or monocyte chemotactic protein-1) and its
receptors chemokine receptor 2 (CCR2) and chemokine
receptor 4 (CCR4) have been implicated in a number of
neuropathologies ranging from traumatic brain injury to
autoimmune diseases [8]. CCL2 can be produced by a
number of cell types in the brain, including neurons [8,9].
The consequences of CCL2 expression are varied and
context-dependent. For example, CCL2 has been shownto activate microglia as well as increase the infiltration of
circulating macrophages [8]. Furthermore, while CCL2
expression is upregulated in a number of neuropathies,
the consequences are detrimental in some disease states
and protective in others [8].
At this time, no data exist concerning the role of che-
mokines in the progression of hepatic encephalopathy due
to acute liver failure. Therefore, the aims of this study
were to assess the expression of CCL2 and its receptors in
a rodent model of hepatic encephalopathy due to acute
liver failure and to determine how CCL2 contributes to
the neurological decline observed in this disorder. This
may help identify one of the signals involved in initiating
the proinflammatory response that occurs during hepatic
encephalopathy.
Methods
Materials
Antibodies against IBA1 were purchased from Wako
Chemicals USA (Richmond, VA, USA). Antibodies against
CCL2, CCR2, and CCR4 were purchased from Genetex
(Irvine, CA, USA). NeuN antibodies were ordered from
Millipore (Billerica, MA, USA). All real-time PCR (RT-PCR)
primers were purchased from SABiosciences (Frederick,
MD, USA). INCB 3284 dimesylate (INCB) and C021
dihydrochloride (C021) were purchased from Tocris Bio-
science (Minneapolis, MN, USA). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise noted, and were of the highest grade available.
Mouse model of hepatic encephalopathy
All in vivo experiments were performed in male C57Bl/6
mice (20 to 25 g; Charles River Laboratories, Wilmington,
MA, USA). Mice were given free access to water and
rodent chow and were housed in constant temperature,
humidity, and 12 h light-dark cycling. Acute liver failure
was induced via a single intraperitoneal (ip) injection of
100 mg/kg of azoxymethane (AOM). In parallel, systemic
inhibition of CCR2 and CCR4 activity was accomplished
via pretreatment with INCB (1 mg/kg/day ip) or C021
(1 mg/kg/day ip) for 3 days prior to injection of AOM.
Following injection, mice were placed on heating pads
adjusted to 37°C and monitored frequently for signs
of neurological decline. To reduce the impacts of
hypoglycemia and dehydration, cage floors were supplied
with hydrogel and rodent chow and after 12 h, and every
subsequent 4 h, mice were injected subcutaneously with
5% dextrose in 250 μL of saline. If mice underwent a 20%
or greater weight loss they were removed from the study.
All animal experiments performed were approved by and
complied with the Baylor Scott & White IACUC regula-
tions on animal experiments (protocol #2011-052-R).
At 8 h following injection (and every 2 h after), body
temperature, weight, and neurological assessments were
McMillin et al. Journal of Neuroinflammation 2014, 11:121 Page 3 of 11
http://www.jneuroinflammation.com/content/11/1/121measured. Neurological functioning was assessed by mea-
suring the pinna reflex, corneal reflex, tail flexion reflex,
escape response reflex, righting reflex, and ataxia, which
were assessed and scored on a scale of 0 (no reflex) to 2
(intact reflex). The neurological score at each time point
was defined as the summation of these reflex scores. In
addition, time to coma (defined as a loss of all reflexes)
was recorded. Tissue was flash frozen and collected at
coma (loss of corneal and righting reflexes) for further
analysis. Mice used for histochemical studies were
transcardially perfused with PBS followed by 4% para-
formaldehyde. Whole brains were removed and placed
into paraformaldehyde for 24 h, after which they were
moved to a 30% sucrose solution for cryoprotection.
Brains were frozen and sectioned using a cryostat for
immunofluorescence imaging.
Liver histology and biochemistry
Paraffin-embedded livers were sectioned into 3 μm sec-
tions and mounted onto positively charged slides (VWR,
Radnor, PA, USA). Slides were deparaffinized and stained
with Hematoxylin QS (Vector Laboratories, Burlingame,
CA, USA) for 1 min followed by staining for 1 min with
eosin Y (Amresco, Solon, OH, USA) and rinsed in 95%
ethanol. The slides were then dipped into 100% ethanol
and subsequently through two xylene washes. Coverslips
were mounted onto the slides using Vectamount moun-
ting media (Vector Laboratories). The slides were viewed
and imaged using an Olympus BX40 microscope with an
Olympus DP25 imaging system (Olympus, Center Valley,
PA, USA).
Serum alanine aminotransferase (ALT) and bilirubin were
assessed using commercially available kits. ALT measure-
ment was performed using a fluorometric activity assay
(Sigma-Aldrich). Total bilirubin was assayed using a total
bilirubin ELISA (CusaBio, Wuha, China). All assays and
subsequent analyses were performed according to manufac-
turers’ instructions.
Real-time PCR
RNA was extracted from flash frozen tissue and RT-PCR
was performed as previously described [10], using com-
mercially available primers designed against mouse CCL2,
IL-1β, IL-6, and glyceraldehyde 3-phosphate dehydrogen-
ase. A ΔΔCT analysis was performed using vehicle-treated
tissue or untreated primary neurons as controls for subse-
quent experiments [11,12]. Data for all experiments are
expressed as mean relative mRNA levels ± SEM. The
sample size for each experiment in each case is indicated
in the figure legends.
Immunoblotting
Immunoblots were performed as previously described
[13] with minor modifications. For western blots, 10%sodium dodecyl sulfate-polyacrylamide gel electropho-
resis gels were loaded with 10 to 20 μg of protein
diluted in Laemmli buffer. Specific primary antibodies
against CCL2, CCR2, CCR4, phosphorylated extracel-
lular signal-regulated kinase 1/2 (pERK1/2), total extracel-
lular signal-regulated kinase 1/2 (tERK1/2), and β-actin
were used along with appropriate fluorescent secon-
dary antibodies (LI-COR, Lincoln, NE, USA). All im-
aging was performed on an Odyssey 9120 Infrared
Imaging System (LI-COR). Data are expressed as fold
change in fluorescent band intensity of target antibody
divided by β-actin or tERK1/2, which were used as
loading controls. The values of vehicle or control
groups were used as a baseline and set to a relative
protein expression value of 1. All treatment groups
were represented as changes of fluorescent band inten-
sity of target antibody to β-actin or tERK1/2 relative to
vehicle or control groups. All band intensity quantifi-
cations were performed using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD, USA). Data
for all experiments were expressed as mean relative
protein ± SEM (n = 3).Immunofluorescence
Free-floating immunostaining was performed on brain
sections using anti-IBA1 immunoreactivity to detect the
morphology and relative staining of microglia. In addition,
CCL2 and NeuN immunostaining were performed.
Immunoreactivity was visualized using fluorescent se-
condary antibodies labeled with Dylight 488 or Cy3
and counterstained with ProLong© Gold Antifade
Reagent containing 4’,6-diamidino-2-phenylindole (DAPI).
Slides were viewed and imaged using a Leica TCS SP5-X
inverted confocal microscope (Leica Microsystems, Buffalo
Grove, IL, USA). Quantification of photomicrographs
was performed by converting images to grayscale, inver-
ting their color and quantifying field staining intensity
with ImageJ software.Statistical analysis
All statistical analyses were performed using Graphpad
Prism software (Graphpad Software, La Jolla, CA, USA).
Results were expressed as mean ± SEM. For data that
passed normality tests, significance was established
using the Student’s t-test when differences between
two groups were analyzed, and analysis of variance
when differences between three or more groups were
compared followed by the appropriate post hoc test. If
tests for normality failed, two groups were compared
with a Mann-Whitney U test or a Kruskal-Wallis ranked
analysis when more than two groups were analyzed.
Differences were considered significant when the P value
was less than 0.05.
McMillin et al. Journal of Neuroinflammation 2014, 11:121 Page 4 of 11
http://www.jneuroinflammation.com/content/11/1/121Results
Microglia activation occurs during AOM-induced hepatic
encephalopathy
Liver damage leading to the development of hepatic
encephalopathy has been previously demonstrated to
be dependent upon increased microglia activation and
subsequent neuroinflammation [7,14]. Therefore, microglia
proliferation and activation were assessed in the brains of
AOM-treated mice. Free-floating immunofluorescence was
performed using the microglia marker IBA1. AOM-treated
mice had a significant increase in IBA1 fluorescence
intensity in both the cortex and cerebellum compared
to vehicle-treated mice, indicative of microgliosis,
which in this study is defined as microglia aggregation in
response to injury or stress and is indicative of a neuro-
inflammatory state (Figure 1A,B). In order to see if indi-
vidual microglia have a shift in their morphology, IBA1
fluorescence was assessed in the cortex and cerebellum,Figure 1 Microglia activation occurs globally in the brain during hepa
cortex and cerebellum from vehicle and AOM-treated mice. (B) Quantificat
vehicle- and AOM-treated mice. (C) IBA1 immunofluorescence (red) in indi
AOM cerebellum. For immunofluorescence quantification analyses * P <0.0identifying that microglia have a more amoeboid appea-
rance with retracted processes in AOM-treated mice
compared to vehicle-treated mice (Figure 1C).
CCL2 is elevated following AOM-induced liver damage
In order to determine if microglia activation was correlated
with increased chemokine expression, neural CCL2 levels
were measured. In the cortex, we observed a significant in-
crease of CCL2 protein in AOM-treated mice (Figure 2A).
In order to see if local increases in mRNA expression were
driving these increases in protein, RT-PCR was performed.
Expression of CCL2 mRNA was significantly upregulated
in the cortex of AOM-treated mice compared to vehicle-
treated mice (Figure 2B). CCL2 immunofluorescence was
found to colocalize with the neuronal marker NeuN, indi-
cating that CCL2 is expressed predominantly in neurons
(Figure 2C). Quantification of this immunofluorescence
demonstrated that AOM-treated mice had significantlytic encephalopathy. (A) Field IBA1 field fluorescence (red) in the
ion of IBA1 field fluorescence in the cortex and cerebellum from
vidual cells in vehicle cortex, AOM cortex, vehicle cerebellum, and
5 compared to vehicle-treated mice, n = 3.
Figure 2 CCL2 levels are elevated following AOM-induced liver failure. (A) CCL2 concentrations in cortex lysates from vehicle and AOM-treated
mice, n = 3. (B) CCL2 mRNA expression in the cortex of vehicle- and AOM-treated mice, n = 3. (C) Immunofluorescence for CCL2 (red) and NeuN
(green) with DAPI (blue) used as a counterstain in vehicle- and AOM-treated mouse cortices. (D) Quantification of CCL2 immunofluorescence in
vehicle- and AOM-treated mouse cortex, n = 3. (E) Serum levels of CCL2 in vehicle- and AOM-treated mice, n = 4. For ELISA, mRNA, and fluorescence
quantification analyses * P <0.05 compared to vehicle-treated mice.
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pared to vehicle-treated mice (Figure 2D). Outside of
the brain, circulating levels of CCL2 were elevated in
AOM-treated mice compared to vehicle-treated mice
(Figure 2E).
Inhibition of CCR2 or CCR4 is protective from AOM-induced
neurological decline
As CCL2 concentrations were systemically upregulated,
the function of CCL2/CCR2 and CCL2/CCR4 receptor
activity in this model was investigated. The protein ex-
pression of CCR2 and CCR4 was found to be unchangedin the cortex following AOM injection (Figure 3A). To
assess the role of CCL2/CCR2 or CCL2/CCR4 signaling
in the neurological complications of acute liver failure,
antagonists against these receptors were injected prior to
AOM administration. Pretreatment with either antagonist
was found to significantly delay the neurological decline
and increase the time taken to reach coma, indicating a
neuroprotective effect of these treatments (Figure 3B,C).
Analyses of liver enzymes after pretreatment with
CCL2 receptor antagonists in AOM-treated mice dem-
onstrated a significant reduction in the levels of ALT
levels (Figure 3D) and bilirubin (Figure 3E) compared
Figure 3 CCR2 and CCR4 signaling play a role in the progression of hepatic encephalopathy. (A) Representative immunoblots
against CCR2 and CCR4 in vehicle- and AOM-treated cortex lysates. (B) Time to coma, in hours, of mice treated with AOM, AOM +
INCB, or AOM + C021, n = 4. (C) Neurological score of mice treated with AOM, AOM + INCB, or AOM + C021, n = 4. Neurological
score calculations are outlined in the methods section. (D) Serum ALT levels in mice treated with vehicle, AOM, AOM + INCB, or
AOM + C021. (E) Bilirubin concentrations in serum for mice administered vehicle, AOM, AOM + INCB, or AOM + C021. (F) Hematoxylin
and eosin stains in liver sections from mice treated with vehicle, AOM, AOM + INCB, or AOM + C021. For time to coma analyses,
* P <0.05 compared to AOM-treated mice. For ALT and bilirubin assays, * P <0.05 compared to vehicle-treated mice, # P <0.05
compared to AOM-treated mice.
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significantly elevated compared to controls indicating the
presence of significant liver damage. This persistence of
liver damage is evident in hematoxylin and eosin-stained
liver sections, which indicate that significant necrosis and
steatosis is still present in mice pretreated with either
INCB or C021 (Figure 3F). Thus, it appears that even
though significant liver damage was still present, pre-
treatment with INCB or C021 prior to AOM administra-
tion improved liver function.CCR2 and CCR4 inhibition reduces microglia activation in
AOM-treated mice
Since CCR2 and CCR4 antagonism were found to reduce
the neurological decline associated with AOM-induced
liver damage, the effects of INCB and C021 on microglia
proliferation and activation were assessed. Measurement
of IBA1 field fluorescence identified that mice treated
with INCB or C021 had significantly less microgliosis
compared to mice treated with AOM alone (Figure 4A,B).
Assessment of microglia morphology in mice treated with
Figure 4 CCR2 and CCR4 inhibition reduces microglia activation. (A) Cortical IBA1 field fluorescence (red) in vehicle-, AOM-, AOM + INCB-,
and AOM + C021-treated mice. (B) Quantification of IBA1 field fluorescence in vehicle-, AOM-, AOM + INCB-, and AOM + C021-treated mice,
n = 3. (C) IBA1 immunofluorescence (red) in individual cells in the cortex of vehicle-, AOM-, AOM + INCB-, and AOM + C021-treated mice. For
quantitative immunofluorescence analyses * P <0.05 compared to vehicle-treated mice.
McMillin et al. Journal of Neuroinflammation 2014, 11:121 Page 7 of 11
http://www.jneuroinflammation.com/content/11/1/121vehicle, AOM, AOM + INCB, and AOM + C021 iden-
tified that treatment of mice with the antagonists
against CCR2 and CCR4 prevented the full activation
of microglia (Figure 4C). Nevertheless, both partially
activated and quiescent microglia were observed in
mice treated with AOM after administration of either
receptor antagonist.
As treatment with both INCB and C021 was able to
reduce microgliosis, validation that these treatments
were reducing CCL2-dependent signaling was required.
Other studies have shown that CCL2-mediated signaling
leads to the phosphorylation of ERK1/2, which can be
used as a measure of CCL2 downstream signaling [15].
Treatment with INCB or C021 was able to significantly
reduce the pERK1/2 to tERK1/2 ratio (Figure 5A) com-
pared to mice treated with AOM alone, indicating that
these treatments are able to reduce downstream CCL2-
mediated signaling. In order to see if this led to functional
changes in neuroinflammation, RT-PCR was performed in
the cortex of AOM-treated mice pretreated with C021
and INCB, which determined that IL-1β and IL-6 mRNA
expression were elevated in AOM-treated mice, effects
that were attenuated in mice pretreated with INCB orC021 (Figure 5B,C). Together, these data indicate that
CCR2 and CCR4 signaling are required for microglia
activation and subsequent production of the proinflamma-
tory cytokines IL-1β and IL-6 following AOM-induced liver
failure.
Discussion
The major findings of this study relate to the role that
CCL2 signaling plays in microglia activation and the subse-
quent proinflammatory response that occurs during hepatic
encephalopathy. The findings from this study demonstrate
that i) CCL2 activation occurs during AOM-induced
neurological decline and mirrors microglia activation, and
ii) inhibiting receptor activity of CCR2 or CCR4 reduces
microglia activation, proinflammatory cytokine expression,
and neurological decline in mice with hepatic encephalop-
athy. These findings suggest that increased CCL2/CCR2
and CCL2/CCR4 signaling, which is present during hepatic
encephalopathy, leads to microglia activation and signifi-
cantly contributes to the proinflammatory response
observed. Thus, reducing CCL2 expression or inhibiting
CCR2 or CCR4 activity may be potential treatment moda-
lities for the management of hepatic encephalopathy.
Figure 5 INCB or C021 pretreatment reduces G-protein signaling pathway activity and proinflammatory cytokine production. (A)
Immunoblots and subsequent analyses for pERK1/2 and tERK1/2 in cortex lysates from mice administered AOM, AOM + INCB, and AOM + C021.
(B) IL-1β mRNA expression in the cortex of vehicle-, AOM-, AOM + INCB-, and AOM + C021-treated mice, n = 3. (C) Cortical IL-6 mRNA expression
in vehicle-, AOM-, AOM + INCB- and AOM + C021-treated mice, n = 3. For pERK1/2 immunoblotting analyses * P <0.05 compared to AOM-treated
mice. For mRNA analyses * P <0.05 compared to vehicle-treated mice.
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rodent models of hepatic encephalopathy, including
hepatic devascularization [14], toxic liver injury [7],
and biliary cirrhosis [16]. Furthermore, microglia acti-
vation has been observed in hepatic encephalopathy
patients, including cirrhotic patients who died from
hepatic coma [17], alcoholic patients that went on to
develop hepatic encephalopathy [18], and in a viral hepa-
titis patient who developed hepatic encephalopathy [1].
Typically, microglia activation during hepatic encephalop-
athy is thought to be caused by elevations of cranial am-
monia, lactate, glutamate, manganese, and neurosteroid
concentrations [19]. Treatments that reduce microglia
activation and are anti-inflammatory, such as the tumor
necrosis factor inhibitor etanercept and therapeutic
hypothermia, have been demonstrated to be protective
against hepatic encephalopathy progression [20,21]. The
results from the current study support the hypothesis
that acute liver failure leads to microglia activation in
the brain.
Previous research has demonstrated that CCL2 is
expressed by a variety of cells in the CNS including neu-
rons, microglia, endothelial cells, and astrocytes and can
induce monocyte recruitment into the CNS [22-24]. Our
studies identified that, during hepatic encephalopathy,
CCL2 is elevated in the brain primarily in neurons.
CCL2 elevation in the brain has been demonstrated in the
bile duct ligation model of peripheral organ inflammation,
where CCL2 or CCR2 knockout were able to reduce brain
monocyte populations compared to wild-type, though up-
regulation of neural CCL2 occurred prior to infiltration of
peripheral immune cells [16]. This study describes what
occurs in the brain following chronic liver injury, but the
specific effects of CCL2 in the brain following hepatic
encephalopathy due to acute liver injury are not known.
However, CCL2 has been implicated in other models of
acute neuroinflammation. For instance, in a mouse model
of controlled cortical impact, a transient upregulation of
CCL2 occurred in the cortex at 24 h, returning to normal
levels within 1 week [25]. Interestingly, in a model of
intracranial hemorrhage, CCL2 knockout mice have
reduced microglia activation only during the first 24 h,
after which the levels are similar to wild-type mice
[26]. Thus, it appears that CCL2 could be involved
with acute microglia activation similar to that observed
during AOM-induced hepatic encephalopathy, though
chronic activation of microglia may be dependent upon
other mechanisms.
In addition to increased brain CCL2 expression, our
data indicate an elevation of CCL2 in the circulation
during the neurological complications of acute liver fail-
ure. Elevated circulating levels of CCL2 have previously
been shown in a number of other neuroinflammatory dis-
orders such as ischemic stroke [27], Alzheimer’s disease[28], and traumatic brain injury [29]. The source of the
CCL2 in the serum during hepatic encephalopathy and in
other neuroinflammatory disorders is unknown. In the
AOM model of hepatic encephalopathy it is conceivable
that CCL2 may be peripherally or centrally derived.
Indeed, elevation of hepatic CCL2 following liver da-
mage has previously been demonstrated in alcoholic
liver disease [30], non-alcoholic steatohepatitis [31],
and in acute liver failure [32]. Furthermore, CCL2 con-
tributes to liver damage and strategies to inhibit CCL2
expression or function appear to be protective in a num-
ber of models of liver injury [33,34].
Here, we demonstrate that inhibition of CCL2 signaling
in the liver using CCR2 and CCR4 antagonists is some-
what hepatoprotective. The data supports that the signifi-
cant parenchymal damage that occurs in AOM mice still
persists following INCB or C021 treatment, though liver
function is improved as measured by both serum ALT and
bilirubin levels. In support of our findings, CCR2 knock-
out mice are resistant to hepatitis and have reduced
infiltration of inflammatory monocytes [35]. Conversely,
studies using an acetaminophen model of liver injury
identified that CCR2 knockout exacerbated liver injury
[36]. Thus, it appears that CCR2-dependent signaling in
the liver is context dependent. Little information exists
regarding the specific role for CCR4 in models of liver
damage. Interestingly, macrophages and other immune
cells are regulated by both CCR2 and CCR4 and thus it is
possible that reducing their activity may prevent immune
cell recruitment to the liver and subsequent acute injury.
It is conceivable that the source of CCL2 that contri-
butes to the neurological decline in AOM-treated mice
may be peripherally-derived, but for this to be reasonable,
CCL2 must be able to cross the blood-brain barrier (BBB).
Interestingly, the BBB is disrupted in AOM-treated mice,
which leads to vasogenic edema [37]; however, the
mechanism by which the BBB is permeabilized is not
clearly defined. CCL2 has been previously shown to
exert an effect on BBB permeability in a number of
models of neuroinflammation. For instance, in a model
of stroke CCL2 knockout mice have decreased BBB
permeability compared to wild-type mice [38]. Also,
in vitro models of the BBB have demonstrated that
CCL2 helps promote permeability of brain endothelial
cell and astrocyte bilayers [39]. Other studies have
found that CCL2 can undergo transcellular transport
across intact endothelial cell monolayers, giving support
that systemic CCL2 may have the capability to generate
neuroimmunological effects in the absence of overt changes
in BBB permeability [40]. The direct contribution of CCL2
on BBB permeability and cerebral edema following acute
liver failure is unknown; however, other studies have shown
that microglia are able to recruit circulating monocytes into
the brain following bile duct resection, a model that can be
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liver injury, and that this recruitment was dependent on
both CCL2 and CCR2 [16]. In the current study, systemic
treatment with INCB and C021 generated effects on both
the liver and brain and this could be due to the improve-
ment of liver function and a subsequent decrease in toxic
metabolites that enter the brain, a reduction of circulating
immune cell recruitment to the brain, or reduction of
cerebral edema. Ongoing studies are being performed to
address the specific mechanisms that INCB and C021
generate their neuroprotective effects during hepatic
encephalopathy.
In humans, microglia have been demonstrated to
express a variety of chemokine receptors, including CCR1,
CCR2, CCR4, CCR5, CXCR1, CXCR3, and CX3CR1, indi-
cating that their function can be regulated by a variety of
chemokines [41]. Even though CCR2 and CCR4 are the
primary receptors for CCL2, it is possible that INCB
and C021 could inhibit the activity of other chemokines.
There are recent reports of CCL2 binding at chemokine
receptor-independent sites, such as the D6 decoy che-
mokine receptor, which leads to sequestration of this
chemokine [42]. This has been demonstrated in primary
adult human astrocytes where CCL2 is able to bind
astrocytes that do not express CCR2 but do express the
D6 decoy chemokine receptor [43]. Thus, it may be pos-
sible that shifts in CCL2/CCR2/CCR4 activity, along
with activities of other chemokines and receptors, play
important roles in the neurological decline associated
with hepatic encephalopathy, though further studies in
this area are still warranted.
Conclusions
The results presented here suggest that, following acute
liver failure, microglia activation via CCL2-induced sig-
naling contributes to the neurological decline associated
with hepatic encephalopathy. Our results suggest that
modulating systemic CCL2 signaling via the use of INCB
or C021 to inhibit CCR2 and CCR4 helps improve liver
function, leads to reduced microglia activation, and reduces
neurological decline compared to mice treated with AOM
alone. Therefore, treatments aimed at reducing circulating
levels of CCL2, or reducing the activity of CCR2 or CCR4,
may be a potential treatment paradigm for patients with
hepatic encephalopathy.
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